C

PriceCitius Oncology

CTOR

Citius Oncology Inc is a specialty pharmaceutical company dedicated to the development and commercialization of critical care products targeting unmet needs with a focus on oncology products.  In addition, Citius completed enrollment in its Phase 2b trial of CITI-002 (Halo-Lido), a topical formulation for the relief of hemorrhoids.

Historical stock price chart and annual return over the past years

-92%

2 years

% Total

CTOR
-57%

2 years

Annual Return

CTOR